XBiotech Balance Sheet Health
Financial Health criteria checks 3/6
XBiotech has a total shareholder equity of $192.1M and total debt of $10.0M, which brings its debt-to-equity ratio to 5.2%. Its total assets and total liabilities are $209.9M and $17.7M respectively.
Key information
5.2%
Debt to equity ratio
US$10.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$183.12m |
| Equity | US$192.12m |
| Total liabilities | US$17.74m |
| Total assets | US$209.85m |
Recent financial health updates
XBiotech (NASDAQ:XBIT) Has Debt But No Earnings; Should You Worry?
Dec 30
Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?
Aug 30Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?
May 13We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate
Feb 09We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely
Oct 25XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans
May 11Recent updates
XBiotech (NASDAQ:XBIT) Has Debt But No Earnings; Should You Worry?
Dec 30Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?
Aug 30XBiotech: Several Shots On Goal In Big Target Market Indications
May 24Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?
May 13We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate
Feb 09We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely
Oct 25We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation
Jun 16XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans
May 11Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares
Mar 18Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential
Jan 08XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity
Nov 19Financial Position Analysis
Short Term Liabilities: XBIT's short term assets ($185.0M) exceed its short term liabilities ($16.0M).
Long Term Liabilities: XBIT's short term assets ($185.0M) exceed its long term liabilities ($1.7M).
Debt to Equity History and Analysis
Debt Level: XBIT has more cash than its total debt.
Reducing Debt: XBIT's debt to equity ratio has increased from 0% to 5.2% over the past 5 years.
Debt Coverage: XBIT's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if XBIT's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 08:51 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
XBiotech Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | NOBLE Capital Markets, Inc. |
| Joseph Catanzaro | Piper Sandler Companies |